Molecular diagnostics in gynaecologic cancer;Molekylærdiagnostiske metoder innen gynekologisk kreft

Tidsskrift for den Norske Laegeforening

Volumn 125, Issue 22, 2005, Pages 3120-3123

  Salvesen, Helga B ^a,b   Iversen, Ole Erik ^a   Tropé, Claes ^c  

^a Haukeland Universitetssjukehus ^*  (Germany)

^b UNIVERSITY OF BERGEN   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER SCREENING; COCHRANE LIBRARY; DNA REPAIR; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; GENETIC SUSCEPTIBILITY; GYNECOLOGIC CANCER; HUMAN; INTERNET; MEDLINE; OVARY CANCER; REVIEW; UTERINE CERVIX CANCER; UTERUS CANCER; WART VIRUS; DIAGNOSTIC PROCEDURE; ENDOMETRIUM TUMOR; FEMALE GENITAL TRACT TUMOR; GENETIC PREDISPOSITION; GENETICS; METHODOLOGY; OVARY TUMOR; PROGNOSIS; UTERINE CERVIX TUMOR; VIRUS INFECTION;

ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENITAL NEOPLASMS, FEMALE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; OVARIAN NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; UTERINE CERVICAL NEOPLASMS;

EID: 28444469174     PISSN: 00292001     EISSN: 00292001     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003; 348: 2339-47.
2. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-99.
3. Sifri R, Gangadharappa S, Acheson LS. Identifying and testing for hereditary susceptibility to common cancers. CA Cancer J Clin 2004; 54: 309-26.
4. Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.
5. Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 1999; 17: 1382-90.
6. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-29.
7. Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-51.
8. Lobb E, Meiser B. Genetic counselling and prophylactic surgery in women from families with hereditary breast or ovarian cancer. Lancet 2004; 363: 1841-2.
9. Jacobs IJ, Skates SJ, MacDonald N et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353: 1207-10.
10. Alexe G, Alexe S, Liotta LA et al. Ovarian cancer detection by logical analysis of proteomic data. Proteomics 2004; 4: 766-83.
11. Trope C, Kaern J, Hogberg T et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol 2000; 11: 281-8.
12. Davidson B, Elstrand MB, McMaster MT et al. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol 2005; 96: 42-7.
13. Yuan ZQ, Sun M, Feldman RI et al. Frequent activation of AKT2 and induction of apoptosis by nhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000; 19: 2324-30.
14. See HT, Kavanagh JJ. Novel agents in epithelial ovarian cancer. Cancer Invest 2004, 22 (suppl 2): 29-44.
15. Rose PG. Endometrial carcinoma. N Engl J Med 1996; 335: 640-9.
16. Wijnen JT, Vasen HF, Khan PM et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Eng J Med 1998; 339: 511-8.
17. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med 2003; 138: 560-70.
18. MacDonald ND, Salvesen HB, Ryan A et al. Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res 2000; 60: 1750-2.
19. Salvesen HB, MacDonald N, Ryan A et al. Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 2000; 6: 3607-13.
20. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004; 444: 213-23.
21. http://www.cancer.gov/clinicaltrials (14.1.2005).
22. Crum CP. The beginning of the end for cervical cancer? N Engl J Med 2002; 347: 1703-5.
23. Franco EL. Are we ready for a paradigm change in cervical cancer screening? Lancet 2003; 362: 1866-7.
24. Wright TC jr., Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003; 348: 489-90.
25. Skjeldestad FE, Hagen B, red. Prekankrøse lidelser i cervix I: Norsk Gynekologisk Forening. Gynekologiske veiledninger. Onkologi. Oslo: Norsk gynekologisk forening, 2002 (evidert 2005). http://www.nhi.no/ngf/
26. Peto J, Gilham C, Fletcher O et al. The cervical cancer epidemic that screening has prevented in the UK. Lancet. 2004; 364: 249-56.
27. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-65.